• Explore /
  • Poster
  • / Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.

Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.

Abstract Poster

Authors

null

Min-Young Lee

Samsung medical center, Seoul, South Korea

Min-Young Lee , Seung Tae Kim , Jeeyun Lee , Se Hoon Park , Young Suk Park , Ho Yeong Lim , Won Ki Kang , Joon Oh Park

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT01130805

Citation

J Clin Oncol 33, 2015 (suppl; abstr 4049)

DOI

10.1200/jco.2015.33.15_suppl.4049

Abstract #

4049

Poster Bd #

159

Abstract Disclosures

Similar Posters

Poster

2016 Gastrointestinal Cancers Symposium

<span>Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin).</span>

Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin).

First Author: Seung Kim

First Author: Ilya Tsimafeyeu

First Author: Pat Gulhati

First Author: Shunji Endo